0000899243-20-026170.txt : 20200923
0000899243-20-026170.hdr.sgml : 20200923
20200923185507
ACCESSION NUMBER: 0000899243-20-026170
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200731
FILED AS OF DATE: 20200923
DATE AS OF CHANGE: 20200923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HURWITZ EDWARD
CENTRAL INDEX KEY: 0001211840
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 201193077
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-31
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001211840
HURWITZ EDWARD
C/O DYNE THERAPEUTICS, INC.
830 WINTER STREET
WALTHAM
MA
02451
1
0
1
0
Common Stock
2020-09-21
4
C
0
4614943
A
4614943
I
See footnote
Common Stock
2020-09-21
4
C
0
245279
A
245279
I
See footnote
Common Stock
2020-09-21
4
C
0
91081
A
91081
I
See footnote
Series A Preferred Stock
2020-07-31
4
P
0
4893347
1.00
A
Common Stock
1475277
13980992
I
See footnote
Series A Preferred Stock
2020-07-31
4
P
0
260077
1.00
A
Common Stock
78409
743076
I
See footnote
Series A Preferred Stock
2020-07-31
4
P
0
96576
1.00
A
Common Stock
29116
275932
I
See footnote
Series B Preferred Stock
2020-08-07
4
P
0
1326313
2.811
A
Common Stock
399867
1326313
I
See footnote
Series B Preferred Stock
2020-08-07
4
P
0
70492
2.811
A
Common Stock
21254
70492
I
See footnote
Series B Preferred Stock
2020-08-07
4
P
0
26176
2.811
A
Common Stock
7893
26176
I
See footnote
Series A Preferred Stock
2020-09-21
4
C
0
13980992
0.00
D
Common Stock
4215076
0
I
See footnote
Series A Preferred Stock
2020-09-21
4
C
0
743076
0.00
D
Common Stock
224025
0
I
See footnote
Series A Preferred Stock
2020-09-21
4
C
0
275932
0.00
D
Common Stock
83188
0
I
See footnote
Series B Preferred Stock
2020-09-21
4
C
0
1326313
0.00
D
Common Stock
399867
0
I
See footnote
Series B Preferred Stock
2020-09-21
4
C
0
70492
0.00
D
Common Stock
21254
0
I
See footnote
Series B Preferred Stock
2020-09-21
4
C
0
26176
0.00
D
Common Stock
7893
0
I
See footnote
On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any.
The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any.
The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
/s/ Richard Scalzo, Attorney-in-Fact
2020-09-23